All Stories

  1. KL-6 as a Biomarker for Adult Patients with Cystic Fibrosis and the Impact of MUC1 Genotype
  2. The burden of autoimmune pulmonary alveolar proteinosis: a systematic review
  3. Sex-specific phenotypes and outcomes in non‑IPF interstitial lung disease: results from the INSIGHTS‑ILD registry
  4. Challenges in diagnosis of sarcoidosis
  5. Racial, Ethnic, Sex, and Gender Equity for Inclusive Interstitial Lung Disease Research: An Official American Thoracic Society Research Statement
  6. Sarcoidosis: A State-Of-The-Art Review
  7. Design of a Phase II randomised, double-blind, placebo-controlled, dose-finding trial of BI 1819479 in patients with idiopathic pulmonary fibrosis
  8. Circulating biomarkers in subjects with progressive pulmonary fibrosis: data from the INBUILD trial
  9. Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis
  10. Summary for clinicians: ERS guidelines on pulmonary alveolar proteinosis
  11. Real-life characteristics and management of patients with fibrosing interstitial lung disease: INSIGHTS-ILD registry
  12. The role of heat shock protein 90 in idiopathic pulmonary fibrosis: state of the art
  13. European Respiratory Society guidelines for the Diagnosis and Management of Pulmonary Alveolar Proteinosis
  14. Pathogenesis-driven treatment of primary pulmonary alveolar proteinosis
  15. Phase 2, Double-Blind, Placebo-controlled Trial of a c-Jun N-Terminal Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
  16. Kidney manifestations of sarcoidosis
  17. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival
  18. Will inhalational GM-CSF replace whole lung lavage as a treatment for autoimmune pulmonary alveolar proteinosis? Many pole positions, not yet the final winner
  19. Pulmonale Alveolarproteinose (PAP)
  20. Pulmonale alveoläre Mikrolithiasis (PAM)
  21. Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
  22. Serum KL-6 as a Candidate Predictor of Outcome in Patients with SARS-CoV-2 Pneumonia
  23. Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial
  24. Serum KL-6 as a Biomarker of Progression at Any Time in Fibrotic Interstitial Lung Disease
  25. MUC5B rs35705950 minor allele associates with older age and better survival in idiopathic pulmonary fibrosis
  26. European Respiratory Society Statement on Familial Pulmonary Fibrosis
  27. Lung cancer in patients with idiopathic pulmonary fibrosis: A retrospective multicentre study in Europe
  28. Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective
  29. COVID-19 in patients with Pulmonary Alveolar Proteinosis A European multicenter study
  30. Genetic testing in interstitial lung disease: An international survey
  31. Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
  32. Targeted therapy for pulmonary alveolar proteinosis: the time is now
  33. Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases
  34. Communicating with patients with idiopathic pulmonary fibrosis: can we do it better?
  35. Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden
  36. Modified GAP index by including serum KL-6 to assess risk of disease progression in patients with interstitial lung diseases (ILD): preliminary results from the VAMOS study
  37. Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPF
  38. Chest radiography or computed tomography for COVID-19 pneumonia? Comparative study in a simulated triage setting
  39. Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPF
  40. S2K Guideline for Diagnosis of Idiopathic Pulmonary Fibrosis
  41. Potential Clinical Utility of MUC5B und TOLLIP Single Nucleotide Polymorphisms (SNPs) in the Management of Patients with IPF
  42. Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis
  43. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)
  44. Ganzlungenlavage bei pulmonaler Alveolarproteinose – Schritt für Schritt
  45. Clinical burden of idiopathic pulmonary fibrosis (IPF): physician and patient perception
  46. Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment
  47. When the Game Changes
  48. Hypersensitivity pneumonitis
  49. The perpetual enigma of bronchoalveolar lavage fluid lymphocytosis in chronic hypersensitivity pneumonitis: is it of diagnostic value?
  50. Looking into the future of sarcoidosis: what is next for treatment?
  51. Shedding light on developmental drugs for idiopathic pulmonary fibrosis
  52. Serum KL‐6 concentrations as a novel biomarker of severe COVID‐19
  53. A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis
  54. Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review
  55. Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis
  56. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis
  57. S2K-Leitlinie zur Diagnostik der idiopathischen Lungenfibrose
  58. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
  59. Genotype in MUC5B-Promoter Polymorphism and Chronic Lung Allograft Dysfunction (CLAD) in a German Cohort: Preliminary Results
  60. S2K-Leitlinie zur Diagnostik der idiopathischen Lungenfibrose
  61. Therapie von Komplikationen und nichtpharmakologisches Management der idiopathischen pulmonalen Fibrose
  62. Azathioprine for Connective Tissue Disease-Associated Interstitial Lung Disease
  63. Baseline High-Resolution CT Findings Predict Acute Exacerbation of Idiopathic Pulmonary Fibrosis: German and Japanese Cohort Study
  64. Therapie der systemischen Sklerose-assoziierten interstitiellen Lungenerkrankung
  65. Quantitative Lipidomics in Pulmonary Alveolar Proteinosis
  66. Shaping the future of an ultra-rare disease
  67. Editorial introductions
  68. Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis
  69. Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials
  70. Correction to: The Burden of Sarcoidosis Symptoms from a Patient Perspective
  71. Pulmonary alveolar proteinosis
  72. The Burden of Sarcoidosis Symptoms from a Patient Perspective
  73. Changes in serum KL-6 levels are associated with the development of chronic lung allograft dysfunction in lung transplant recipients
  74. Erratum zu: Differenzialdiagnose interstitieller Lungenerkrankungen – „Interstitial pneumonia with autoimmune features“ (IPAF)
  75. Utility of Anti-DSF70 Antibodies to Predict Connective Tissue Disease in Patients Originally Presenting with Idiopathic Interstitial Pneumonia
  76. Nailfold Capillaroscopy Characteristics of Antisynthetase Syndrome and Possible Clinical Associations: Results of a Multicenter International Study
  77. Differenzialdiagnose interstitieller Lungenerkrankungen
  78. Die „Rheumalunge“ in der Computertomographie: radiologische Manifestationen der rheumatoiden Arthritis
  79. The Management of Patients With Idiopathic Pulmonary Fibrosis
  80. Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey
  81. Patientenfragebogen zur Erfassung der Ursachen interstitieller und seltener Lungenerkrankungen – klinische Sektion der DGP
  82. Patients with IPF and lung cancer: diagnosis and management
  83. German Guideline for Idiopathic Pulmonary Fibrosis – Update on Pharmacological Therapies 2017
  84. Phenotypes of organ involvement in sarcoidosis
  85. Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Uncertainties and Controversies
  86. Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis
  87. Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis
  88. Serum YKL-40 in workers at an indium-tin oxide production facility - Reply
  89. Idiopathic pleuroparenchymal fibroelastosis (PPFE) – A case study of a rare entity
  90. Therapeutic targets in idiopathic pulmonary fibrosis
  91. Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries
  92. Differential diagnosis of granulomatous lung disease: clues and pitfalls
  93. Serum YKL-40 is a reliable biomarker for pulmonary alveolar proteinosis
  94. S2k-Leitlinie Idiopathische Lungenfibrose – Update zur medikamentösen Therapie 2017
  95. FAM13A polymorphism as a prognostic factor in patients with idiopathic pulmonary fibrosis
  96. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone
  97. Coagulation factor XII regulates inflammatory responses in human lungs
  98. Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis
  99. Daily Home Spirometry: A New Milestone in the Field of Pulmonary Fibrosis
  100. Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
  101. Deutschsprachige Validierung des „Kingʼs Brief Interstitial Lung Disease (K-BILD)“ Lebensqualitätsfragebogens für interstitielle Lungenerkrankungen
  102. New insights on patient-reported outcome measures in idiopathic pulmonary fibrosis
  103. Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures
  104. Epidemiologie und klinisches Erscheinungsbild der Sarkoidose
  105. A Global Survey on Whole Lung Lavage in Pulmonary Alveolar Proteinosis
  106. European idiopathic pulmonary fibrosis Patient Charter: a missed opportunity
  107. MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis
  108. How to handle IPF – the new Portuguese consensus document
  109. An Important Step Forward, but Still a Way to Go
  110. Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis
  111. Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
  112. Pulmonary alveolar proteinosis in a cat
  113. European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers
  114. Pulmonale Alveolarproteinose
  115. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
  116. New guideline on treatment of idiopathic pulmonary fibrosis
  117. GATA2 deficiency in children and adults with severe pulmonary alveolar proteinosis and hematologic disorders
  118. Positionspapier zur Bedeutung der forcierten Vitalkapazität für Patienten mit idiopathischer Lungenfibrose (IPF)
  119. Facts and promises on lung biomarkers in interstitial lung diseases
  120. Diagnosis of Sarcoidosis
  121. Update on therapeutic management of idiopathic pulmonary fibrosis
  122. Extracellular 20S proteasome in BAL and serum of patients with alveolar proteinosis
  123. MUC5Bpromoter polymorphism in Japanese patients with idiopathic pulmonary fibrosis
  124. Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives
  125. Alveolar and intraparenchymal proteasome in sarcoidosis
  126. Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic?
  127. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis
  128. Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease
  129. Interstitial lung disease
  130. Differences in serum SP-D levels between German and Japanese subjects are associated with SFTPDgene polymorphisms
  131. CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases
  132. The Ambitious Goal of Validating Prognostic Biomarkers for Systemic Sclerosis-related Interstitial Lung Disease
  133. Macrolides inhibit cytokine production by alveolar macrophages in bronchiolitis obliterans organizing pneumonia
  134. Klinische Erfahrungen mit Pirfenidon in der Therapie der idiopathischen Lungenfibrose
  135. Sarkoidose
  136. Klinische Erfahrungen mit Pirfenidon in der Therapie der idiopathischen Lungenfibrose
  137. Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosis
  138. Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levels
  139. Diagnostic approach to interstitial pneumonias in a single centre: report on 88 cases
  140. Hypersensitivity Pneumonitis
  141. Wash-out kinetics and efficacy of a modified lavage technique for alveolar proteinosis
  142. Chronic Hypersensitivity Pneumonitis
  143. KL-6, a Human MUC1 Mucin, as a prognostic marker for diffuse alveolar hemorrhage syndrome
  144. Self-reported asthma and respiratory symptoms among Italian amateur athletes
  145. Whole-Lung Lavage: A Successful Treatment for Restoring Acinar Ventilation Distribution in Primary Acquired Pulmonary Alveolar Proteinosis
  146. Comparison of serum KL-6 versus bronchoalveolar lavage neutrophilia for the diagnosis of bronchiolitis obliterans in lung transplantation
  147. Pulmonary alveolar proteinosis: New insights from a single-center cohort of 70 patients
  148. Therapie der Lungenfibrose
  149. Diagnostic Modalities in Sarcoidosis: BAL, EBUS, and PET
  150. A female soccer player with recurrent haemoptysis and iron deficiency anaemia: idiopathic pulmonary haemosiderosis (IPH)--case report and literature review
  151. Angiogenic and Angiostatic Chemokines in Idiopathic Pulmonary Fibrosis and Granulomatous Lung Disease
  152. To BAL or Not to BAL: Is This a Problem in Diagnosing IPF?
  153. Die bronchoalveoläre Lavage aus klinischer Sicht
  154. Significance of Bronchoalveolar Lavage for the Diagnosis of Idiopathic Pulmonary Fibrosis
  155. Acid reflux into the oesophagus does not influence exercise-induced airway narrowing in bronchial asthma
  156. Bronchoalveolar Lavage in Other Interstitial Lung Diseases
  157. Omeprazole reduces the response to capsaicin but not to methacholine in asthmatic patients with proximal reflux
  158. Biomarkers